SecBot SecBot
8-K ·Filed Aug 10, 2026

ORKA

Oruka Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC0001213900-26-086933
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Key catalysts over the next 6 months: EVERLAST-A Week 28 data (end of Q3 2026), EVERLAST-B Week 16 data (Q4 2026), and 52-week EVERLAST-A data (December 2026). Activist pressure from Fairmount Funds Management adds scrutiny to pipeline execution and capital allocation. Monitor for any changes in activist strategy or board engagement ahead of data readouts.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

ORKA drug pipeline →

ORKA-001

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2b
Time to market
If Phase 3 trials begin in 1H 2027 and run successfully, a BLA submission and potential FDA approval would likely be several years away, possibly in the 2029-2030 timeframe. The company has stated its $1.1 billion cash position funds operations through a BLA filing.
Next catalyst
None dated

What to watchThe key catalyst to watch is the EVERLAST-A 52-week data expected in December 2026, which will demonstrate whether ORKA-001's skin-clearing responses hold up a full year after just two doses. Strong durability would reinforce the ultra-durable dosing thesis and support the Phase 3 design. Weak durability would challenge the core value proposition. Phase 3 initiation in 1H 2027 and ORKA-002 Phase 2 data in Q1 2027 are secondary catalysts. The $1.1B cash runway removes financing overhang through a BLA filing.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$105.14
T+0 close · Aug 10, 2026 · via day close
Latest settled
−5.32%
T+60 · $99.55
Vs SPY
−2.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $105.14entry
  2. T+1 · 3mo ago −0.44%α −0.12% · $104.68
  3. T+5 · 3mo ago +7.15%α +7.20% · $112.66
  4. T+20 · 2mo ago −10.30%α −9.39% · $94.31
  5. T+60 · 14d ago −5.32%α −2.90% · $99.55
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The company highlighted key upcoming catalysts including Week 28 data from EVERLAST-A and Week 16 data from EVERLAST-B, while maintaining a $1.1 billion cash position expected to fund operations through a BLA filing for ORKA-001. The filing is being evaluated in the context of activist investor Fairmount Funds Management's disclosed stake from July 2026.

Key Financial Metrics

Revenue
$0.00
est $0.00

Key Facts

  • Net loss of $41.2 million for Q2 2026, compared to $24.6 million for Q2 2025
  • Cash, cash equivalents and marketable securities of $1.1 billion as of June 30, 2026
  • R&D expenses increased to $43.3 million from $24.1 million year-over-year
  • EVERLAST-B Phase 2b trial fully enrolled with 187 subjects; Week 16 data expected in Q4 2026
  • Week 28 data from EVERLAST-A expected at end of Q3 2026; 52-week data expected December 2026
  • Phase 3 program for ORKA-001 expected to begin in 1H 2027
  • ORCA-SURGE Week 16 data accelerated to Q1 2027
  • ORCA-SPLASH Phase 2 trial in hidradenitis suppurativa initiated
  • ORKA-004 (anti-TL1A antibody) to enter clinic in Q4 2026
  • Amended IL-23 license with Paragon Therapeutics to include all therapeutic areas including IBD
  • Activist investor Fairmount Funds Management filed SC 13D/A on July 2, 2026
  • Upsized $700 million public offering priced in April 2026

Financial Impact

Net loss widened by $16.6 million year-over-year to $41.2 million; cash position of $1.1 billion provides runway through BLA filing

net losscash positionR&D expenses

Risk Factors

  • Clinical trial data readouts may fail to meet efficacy or safety expectations
  • Activist investor may push for strategic changes or board representation
  • Cash burn rate is increasing as R&D spending grows with expanded pipeline
  • Competitive landscape in IL-23 and IL-17 biologics remains intense

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-086933
Document: ea0301312-8k_oruka.htm0001213900-26-086933
Document: 0001213900-26-086933-index-headers.html0001213900-26-086933
Document: 0001213900-26-086933-index.html0001213900-26-086933
Document: 0001213900-26-086933.txt0001213900-26-086933
8-K Data (Synthetic)0001213900-26-086933

Track record

40 reports on ORKA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens Wed (9h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026